Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal of Oregon.
Press releases published on July 7, 2025
Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema
Ingelheim, Germany, July 7, 2025 – Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision …
OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025
Oxford, United Kingdom – 7th July 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that …
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh …
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer …
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health …
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX-801 confers durable protection after a single dose TNX-801 is well tolerated in immunocompromised animals, without evidence of …
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development …
VitalHub Announces Acquisition of Novari Health Inc.
TORONTO, July 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Novari Health Inc. (“Novari”), a leading healthcare software provider of patient …
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions. Biomarker …
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo- …
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: …
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it has entered into an …
PathMaker Neurosystems Announces Publication of First Study Demonstrating Increased Survival in an ALS Mouse Model After Treatment With Non-Invasive Neuromodulation
Boston, MA and Providence, RI, July 07, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for treating Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig …
First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy
PARIS, July 07, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been …
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But …
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, July 7, 2025 – Eleva, a pioneer in discovering and …
ONWARD Medical Adds Entrepreneur and Neurotechnology Thought Leader Tim Denison, PhD to its Board of Directors
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Denison is Professor of Clinical Neurosciences at the University of Oxford and was previously Vice President of Research …
Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health
SHELTON, Conn., July 06, 2025 (GLOBE NEWSWIRE) -- Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EGT Synbio, headquartered in Shanghai, China, has …